በማስተዋወቅ ላይ በሲንጋፖር ውስጥ የ CAR ቲ-ሴል ሕክምና – a groundbreaking and revolutionary approach to cancer treatment. The National University Cancer Institute, Singapore (NCIS) has developed an innovative therapy that uses the immune system to fight cancer. Unlike traditional chemotherapy, CAR T Cell Therapy is customized, using the modification of a patient’s own blood cells to specifically target and eliminate cancer cells. The use of gamma-delta T cells from healthy donors improves the quality of CAR-T cells while potentially cutting treatment costs, making this therapy even more attractive. This method, developed by CytoMed Therapeutics, represents a substantial advancement in the area. The Health Sciences Authority has approved a phase 1 clinical trial that will recruit healthy blood donors for testing and patients with resistant advanced cancers for treatment. This non-personalized yet effective strategy has the potential to improve cancer care in Singapore, providing hope and new opportunities for patients and their families.
የ CAR ቲ-ሴል ሕክምና በሲንጋፖር - የአሁኑ ሁኔታ
የመኪና-T cell therapy has become a game-changer in the way cancer is treated, and Singapore is very excited about this new therapy. Singapore has made a lot of progress in adopting CAR-T cell therapy through ክሊኒካዊ ሙከራዎች, ሽርክና እና የቁጥጥር ድጋፍ. ይህም ታካሚዎችን ረድቷል እና ለካንሰር እንክብካቤ መሻሻል አስተዋጽኦ አድርጓል. ሲንጋፖር አሁንም በCAR-T የሕዋስ ሕክምና ከፍተኛ ደረጃ ላይ ትገኛለች ምክንያቱም ምርምርን ስለምትቀጥል እና ጥሩ የጤና አጠባበቅ ሥርዓት ስላላት። CAR ቲ-ሴል ቴራፒ በሲንጋፖር የካንሰር ታማሚዎችን እና ቤተሰቦቻቸውን ተስፋ በመስጠት ፍጥነትን አግኝቷል።
በርካታ ክሊኒካዊ ሙከራዎች በ ብሔራዊ ዩኒቨርሲቲ ሆስፒታል, ሲንጋፖር, Chimeric Agent Receptor (CAR) T-cell therapy is developing at a very fast pace in Singapore. Oscar Saxelby-Lee suffers from ፈጣን ሊምፎብላስቲክ ሉኪሚያ, a disease that has resisted all treatments. The five-year-old from the United Kingdom is in Singapore for a procedure that has never been given to one other infant on the planet. The boy flew in from Worcester, England, for a new type of therapy that involves drawing immune cells from a patient’s blood and implanting them with a Chimeric Antigen Receptor (CAR-T).
የሲንጋፖር ጤና ሳይንስ ባለስልጣን (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue, and gene therapy products (CTGTP) regulatory framework. HSA approved Kymriah for the treatment of pediatric and young adult patients from 2 to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell ሊምፎማ (DLBCL) after two or more lines of systemic therapy.
CAR T cells, also known as Chimeric Antigen Receptor T cells, are immune cells that play an important part in CAR T Cell Therapy. These specialized T cells are engineered in a laboratory to express a chimeric antigen receptor on their surface. CAR T cells, also known as Chimeric Antigen Receptor T cells, are immune cells that play an important part in CAR T Cell Therapy. In a laboratory, these specialized T cells are designed to express a chimeric antigen receptor on their surface. This receptor is programmed to recognize specific proteins on the surface of cancer cells known as antigens. When the CAR T cells are identified by the immune system, they bind to the cancer cells, triggering a robust immune response. CAR ቲ ሴሎች that have been activated grow and launch a targeted attack on cancer cells, effectively destroying them.
በሲንጋፖር ውስጥ በ CAR T የሕዋስ ሕክምና ምን ዓይነት ሁኔታዎች ሊታከሙ ይችላሉ?
CAR T Cell Therapy is a kind of advanced immunotherapy that has shown significant effectiveness in treating specific conditions, particularly targeting patients facing challenging scenarios. This advanced therapy is particularly well-suited for individuals diagnosed with relapsed aggressive forms of Acute Lymphoblastic Leukemia (ALL), multiple myeloma, and cases of relapse in ያልሆነ ሆጅኪንስ ሊምፎማ, such as Diffuse Large B-cell Lymphoma (DLBCL). This is especially important when traditional treatments have failed and at least two past treatment approaches have proven ineffective in reaching the desired results. Thus, CAR T-Cell Therapy emerges as a promising therapy option for patients suffering from leukemia and lymphoma, providing them a beacon of hope and the promise for improved treatment outcomes in Singapore.
Patients between the ages of 3 Years to 70 Years have tried CAR T-Cell therapy for different types of የደም ካንሰር and is very effective. Many centers have claimed success rates of more than 80%. The optimum candidate for CAR T-cell therapy at this time is a juvenile with acute lymphoblastic leukemia or an adult with severe B-cell lymphoma who has already had two lines of ineffective therapy.
ሳይቶኪን መልቀቂያ ሲንድሮም (CRS)፦ The most prevalent and possibly significant side effect of CAR T-cell treatment is cytokine release syndrome (CRS). The flu-like symptoms, including fever, exhaustion, headaches, and muscle pain, are brought on by the modified T cells’ production of cytokines. In extreme circumstances, CRS may result in a high temperature, hypotension, organ failure, and even potentially fatal consequences.
ዕጢ ሊሲስ ሲንድሮም (ቲኤልኤስ): After CAR T-cell therapy, it’s possible in some circumstances for substantial amounts of cell contents to be released into the bloodstream due to the rapid killing of እብጠት cells. This may result in metabolic abnormalities, such as excessive potassium, uric acid, and phosphate levels, which may damage the kidneys and cause other problems.
